^
    Apply
    Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NRG-GY023) (NCT04739800)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/10/2021
    Primary completion :
    01/26/2023
    Completion :
    06/14/2025
    PD-L1 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • cisplatin • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • capecitabine • Talzenna (talazoparib) • Piqray (alpelisib) • enzalutamide • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • eribulin mesylate • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • methotrexate • Truqap (capivasertib) • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • carmustine • Erivedge (vismodegib) • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • melphalan • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • fludarabine IV • Zynyz (retifanlimab-dlwr) • avadomide (CC-122) • Ostarine (enobosarm) • vistusertib (AZD2014) • mesna • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • lorvotuzumab mertansine (IMGN901) • Xofigo (radium Ra-223 dichloride) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ieramilimab (LAG525) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • levoleucovorin calcium • methotrexate IV • Pertuvia (pertuzumab biosimilar) • sapitinib (AZD8931) • Vasforda (bevacizumab biosimilar)
    Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY004) (NCT02446600)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    03/28/2016
    Primary completion :
    02/23/2020
    Completion :
    08/23/2025
    BRCA1 • BRCA2 • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    05/23/2016
    Primary completion :
    07/07/2022
    Completion :
    08/09/2025
    BRCA1 • BRCA2 • HRD • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (BAROCCO) (NCT03314740)
    Phase 2
    Mario Negri Institute for Pharmacological Research
    Completed
    Last update posted :
    01/10/2025
    Initiation :
    06/12/2017
    Primary completion :
    04/01/2021
    Completion :
    04/01/2021
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • paclitaxel • Recentin (cediranib)
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    10/31/2024
    Initiation :
    04/14/2010
    Primary completion :
    10/31/2018
    Completion :
    02/13/2025
    BRCA • MUC16
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCI-2015-01097) (NCT02498613)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    08/31/2016
    Primary completion :
    06/22/2022
    Completion :
    04/10/2025
    EGFR • HER-2 • ER • PGR
    |
    HER-2 expression • ALK mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (NCT02484404)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    06/29/2015
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (COCOS) (NCT02502266)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    05/03/2016
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) (NCT03851614)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    04/08/2019
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    HRD • CD4
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (NCT01364051)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    05/25/2011
    Primary completion :
    06/06/2019
    Completion :
    03/07/2025
    CASP3
    |
    Koselugo (selumetinib) • Recentin (cediranib)
    Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (NCI-2019-04148) (NCT04090567)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    07/28/2020
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    HER-2 • ER • BRCA
    |
    ER positive • HER-2 negative
    |
    Lynparza (olaparib) • ceralasertib (AZD6738) • Recentin (cediranib)